Efectos y seguridad del perfluorohexiloctano en la superficie ocular y el endotelio corneal

  1. A.J. Mateo Orobia 36
  2. A. Blasco-Martinez 36
  3. P. Rodríguez-Ausín 1
  4. L.E. Pablo Júlvez 46
  5. N. Güemes Villahoz 2
  6. E. del Prado Sanz 36
  7. M. Satué Palacián 6
  8. J.M. Benítez-del-Castillo 25
  1. 1 Hospital Universitario de Torrejón
    info

    Hospital Universitario de Torrejón

    Torrejon de Ardoz, España

  2. 2 Hospital Clínico San Carlos de Madrid
    info

    Hospital Clínico San Carlos de Madrid

    Madrid, España

    ROR https://ror.org/04d0ybj29

  3. 3 Servicio de Oftalmología, Hospital Provincial Nuestra Señora de Gracia, Zaragoza, España
  4. 4 Universidad de Zaragoza
    info

    Universidad de Zaragoza

    Zaragoza, España

    ROR https://ror.org/012a91z28

  5. 5 Universidad Complutense de Madrid
    info

    Universidad Complutense de Madrid

    Madrid, España

    ROR 02p0gd045

  6. 6 Instituto de Investigación Sanitaria Aragón
    info

    Instituto de Investigación Sanitaria Aragón

    Zaragoza, España

Show affiliations +
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2020

Volume: 95

Issue: 11

Pages: 538-543

Type: Article

DOI: 10.1016/J.OFTAL.2020.05.016 DIALNET GOOGLE SCHOLAR

More publications in: Archivos de la Sociedad Española de Oftalmologia

Abstract

Objective To evaluate the effects and safety of topical drops of perfluorohexyloctane (F6H8) on the ocular surface and the corneal endothelium. Methods Forty-five patients (90 eyes) diagnosed with dry eye disease were recruited and prescribed treatment with F6H8 as part of a six-month prospective multicentre study. Variables in corneal staining were documented using the National Eye Institute/Industry Workshop scale. The conjunctival variables included using the Oxford scale, as well as corneal parameters, such as central corneal thickness, cell density, coefficient of variation, hexagonality, and mean cell area, at the start of the study, and at 3 months and 6 months. Compliance and satisfaction with the treatment were measured. Results F6H8 drops reduced mean corneal staining based on the NEI scale in compliant patients to a mean of −0.84 ± 1.95 at 3 months (P=.001) and to −1.65 ± 2.42 at 6 months (P<.001). Conjunctival staining at 6 months showed a mean decrease of −0.13 (P=.319). The endothelial parameters did not show a significant difference, in contrast to the central corneal thickness that showed a statistically significant decrease (545.30 ± 32.25 at the start of the study to 538.40 ± 31.36 after 6 months, P=.009). At the end of the study, 46% of patients reported feeling subjectively better, 40.5% felt the same, and 13.5% felt subjectively worse. Conclusions Topical treatment with F6H8 for dried eye disease did not alter the measured variables of the corneal endothelium, but showed improvement in corneal staining and satisfaction.

Data source: Dialnet